Mr. Vic Neufeld reports

APHRIA COMMENTS ON TODAY'S GLOBE AND MAIL STORY ON PESTICIDE USE AND REAFFIRMS ITS COMMITMENT TO QUALITY AND SAFETY; APHRIA WELCOMES INDEPENDENT PRODUCT TESTING AS A MEASURE TO PROTECT PATIENT SAFETY

Aphria Inc. has always prided itself on being an industry leader when it comes to the adherence of good production practices in the cultivation of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

Despite most licensed producers taking great care to provide safe and effective products, there are still reports surfacing regarding the presence of harmful pesticides in regulated medical cannabis. "We support the use of independent evaluations and testing of medical cannabis as a necessary measure to protect the safety of Canadians," said Vic Neufeld, chief executive officer of Aphria.

Patients rely on a safe and high-quality product to meet their medical needs and it is critically important that all products sold through the ACMPR adhere to the strict guidelines established by Health Canada to ensure that their needs are met.

"Aphria has always held itself to the highest standards when it comes to the production and cultivation of medical cannabis. This commitment stems from over 40 years of experience balancing the science, experience, and economics of growing high-quality and consistent products for commercial scale sales," said Cole Cacciavillani, co-founder.

Aphria relies on a strict quality management program that continuously tests for pesticides and monitors all suppliers to ensure that any products used exceed the minimum standards set to comply with Health Canada's regulations.

We have a good thing growing.

About Aphria

Aphria produces, supplies and sells medical cannabis. The company is the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.

We seek Safe Harbor.